Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of Pyroglutamate Rongliflozin in Liver Damage
NCT05427682Phase 1Completed
- Sponsor
- Sunshine Lake Pharma
- Start
- Apr 2022
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of pyroglutamate rongliflozin in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Sunshine Lake Pharma. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Concentration-Time Curve and 1 more. Started Apr 2022; status: completed.
02
Drugs
pyroglutamate rongliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05427682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05427682.